AXIOMScientific Capital

Pipeline

Where every asset stands, stage by stage.

A single timeline from IP filing to market. Progress is only recognised when the corresponding evidence package is approved by the Scientific Committee — never to justify a higher valuation.

AXW-001Oral-dissolving solid matrix technology platform — functional no-added-sugar lollipop containing protected lactase
Industrial scale-up · TRL 7
Development phase: Phase 3 — Pilot / Clinical ValidationAsset type: PlatformIndicative valuation: Under evaluation
AXW-002AURA HEALTH FINANCE — Behavioral Health & Financial Intelligence Platform
Field pilot · TRL 6
Development phase: Phase 3 — Pilot / Clinical ValidationAsset type: PlatformIndicative valuation: Under evaluation
AXW-003ABIP Nutritional Phytochemical Platform™
Scientific validation · TRL 5
Development phase: Phase 2 — Validated PrototypeAsset type: PlatformIndicative valuation: Under evaluation
AXW-004ABIP — Pilot study protocol for nutritional intervention and field validation
Field pilot · TRL 6
Development phase: Phase 3 — Pilot / Clinical ValidationAsset type: ProtocolIndicative valuation: Under evaluation
AXW-005ABIP — Multicomponent functional nutritional formulation for intervention in child malnutrition (ownership-corrected version)
IP filed · TRL 4
Development phase: Phase 2 — Validated PrototypeAsset type: FormulationIndicative valuation: Under evaluation
AXW-006ABIP — Multicomponent functional nutritional formulation for intervention in child malnutrition
Scientific validation · TRL 5
Development phase: Phase 2 — Validated PrototypeAsset type: FormulationIndicative valuation: Under evaluation
AXW-007ABIP — Integrated platform for nutritional, cognitive and bioeconomic intervention in a real-world setting (SUS)
Field pilot · TRL 6
Development phase: Phase 3 — Pilot / Clinical ValidationAsset type: PlatformIndicative valuation: Under evaluation
AXW-008BioCurauá Project — Curauá gM GlucoCare
Scientific validation · TRL 5
Development phase: Phase 2 — Validated PrototypeAsset type: R&D projectIndicative valuation: Under evaluation
AXW-009CannabiMod-P™ Onco
Scientific validation · TRL 4
Development phase: Phase 2 — Validated PrototypeAsset type: TechnologyIndicative valuation: Under evaluation
AXW-010CellRex™ Cellular Reprogrammer for Nutritional Rehabilitation
IP filed · TRL 3
Development phase: Phase 1 — Concept / PrototypeAsset type: TechnologyIndicative valuation: Under evaluation
AXW-011NutraSeq™
Scientific validation · TRL 4
Development phase: Phase 2 — Validated PrototypeAsset type: TechnologyIndicative valuation: Under evaluation
AXW-012ImmunoAfrica™
Field pilot · TRL 5
Development phase: Phase 3 — Pilot / Clinical ValidationAsset type: R&D projectIndicative valuation: Under evaluation
AXW-013ZimKids Cognition™
Field pilot · TRL 6
Development phase: Phase 3 — Pilot / Clinical ValidationAsset type: R&D projectIndicative valuation: Under evaluation
AXW-014NutraRegen™ Adaptive Metabolic Modulator for Severe Malnutrition and Cachexia
Scientific validation · TRL 5
Development phase: Phase 2 — Validated PrototypeAsset type: FormulationIndicative valuation: Under evaluation
AXW-015HERBAL SCIENCE For Men's Health
Market ready · TRL 8
Development phase: Phase 4 — Market ValidatedAsset type: ProductIndicative valuation: Under evaluation
AXW-016Improve For Man Line — Inovattis Health Science
Market ready · TRL 8
Development phase: Phase 4 — Market ValidatedAsset type: ProductIndicative valuation: Under evaluation
AXW-017Brain Kids Global Project — Child cognitive and emotional supplementation with international scientific validation
Industrial scale-up · TRL 7
Development phase: Phase 3 — Pilot / Clinical ValidationAsset type: R&D projectIndicative valuation: Under evaluation
AXW-018NitraBeet™ — Cardiovascular bioactive complex of natural beetroot nitrates and nitrites with encapsulated magnesium
Scientific validation · TRL 4
Development phase: Phase 2 — Validated PrototypeAsset type: FormulationIndicative valuation: Under evaluation
AXW-019NeuroFlow Kids™ — Support technology for child neurocognitive development in dyslexia and related difficulties
Scientific validation · TRL 3
Development phase: Phase 2 — Validated PrototypeAsset type: TechnologyIndicative valuation: Under evaluation